keyword
MENU ▼
Read by QxMD icon Read
search

managment tnbc

keyword
https://www.readbyqxmd.com/read/27882217/multiple-effects-of-xihuang-pill-aqueous-extract-on-the-hs578t-triple-negative-breast-cancer-cell-line
#1
Wenxian Zheng, Shuyan Han, Shantong Jiang, Lina Pang, Xiaohong Li, Xijuan Liu, Minhua Cao, Pingping Li
The management of triple-negative breast cancer (TNBC) is challenging due to the aggressive behavior, lack of therapeutic options and relatively poor prognosis. Xihuang pill (XHP) is a well-known Traditional Chinese Medicine with anticancer activity. The aim of the present study was to investigate whether the aqueous extract of XHP (AEXHP) has anti-proliferative activity against the Hs578T TNBC cell line, and to elucidate its molecular mechanisms of action. First, an MTT assay was used to evaluate the anti-proliferative activity of AEXHP on the Hs578T cell line; furthermore, the cell cycle distribution, mitochondrial membrane potential and apoptotic rate were determined by flow cytometry, and western blot analysis was used to assess the expression of apoptosis and cell cycle regulatory proteins to investigate the mechanisms of action...
November 2016: Biomedical Reports
https://www.readbyqxmd.com/read/27856201/daily-practice-management-of-pt1a-b-pn0-breast-carcinoma-a-prospective-french-odissee-cohort-study
#2
Florence Dalenc, Frédérique Penault-Llorca, Monique Cohen, Gilles Houvenaeghel, Jean-Marc Piat, Philippe Liegeois, Laurent Puyuelo, Jean-Philippe Suchaud, Mohammed Zouai, Magali Lacroix-Triki, Nina Radosevic-Robin, Chahinez Benkanoun, Hanane Attar-Rabia, Marie-Pierre Chauvet, Joseph Gligorov, Yazid Belkacemi
BACKGROUND: Most breast cancer (BC) tumors ≤10 mm have an excellent prognosis. The subgroups with a higher risk for distant recurrence requiring adjuvant systemic therapy are not precisely defined in current international guidelines. PATIENTS AND METHODS: The OBSERVATOIRE DES PETITS CANCERS DU SEIN HER2 +/- (ODISSEE) study was a prospective, multicenter, cohort study that aimed to describe the daily adjuvant management and outcome of 616 patients with unifocal, invasive pT1a-b pN0 nonmetastatic BC who underwent surgery...
August 31, 2016: Clinical Breast Cancer
https://www.readbyqxmd.com/read/27817751/novel-insight-into-triple-negative-breast-cancers-the-emerging-role-of-angiogenesis-and-antiangiogenic-therapy
#3
Cornelia Braicu, Roxana Chiorean, Alexandru Irimie, Sergiu Chira, Ciprian Tomuleasa, Emilian Neagoe, Angelo Paradiso, Patriciu Achimas-Cadariu, Vladimir Lazar, Ioana Berindan-Neagoe
Triple-negative breast cancer (TNBC) is a heterogeneous group of tumours characterised by lack of expression of oestrogen-, progesterone- and human epidermal growth factor receptors. TNBC, which represents approximately 15% of all mammary tumours, has a poor prognosis because of an aggressive behaviour and the lack of specific treatment. Accordingly, TNBC has become a major focus of research into breast cancer and is now classified into several molecular subtypes, each with a different prognosis. Pathological angiogenesis occurs at a late stage in the proliferation of TNBC and is associated with invasion and metastasis; there is an association with metabolic syndrome...
November 7, 2016: Expert Reviews in Molecular Medicine
https://www.readbyqxmd.com/read/27816751/growth-hormone-releasing-hormone-induced-transactivation-of-epidermal-growth-factor-receptor-in-human-triple-negative-breast-cancer-cells
#4
Eva Vacas, Laura Muñoz-Moreno, Pedro L Valenzuela, Juan C Prieto, Andrew V Schally, María J Carmena, Ana M Bajo
Triple-negative breast cancer (TNBC) is a subset of breast cancers which is negative for expression of estrogen and progesterone receptors and human epidermal growth factor receptor-2 (HER2). Chemotherapy is currently the only form of treatment for women with TNBC. Growth hormone-releasing hormone (GHRH) and epidermal growth factor (EGF) are autocrine/paracrine growth factors in breast cancer and a substantial proportion of TNBC expresses receptors for GHRH and EGF. The aim of this study was to evaluate the interrelationship between both these signaling pathways in MDA-MB-468 human TNBC cells...
December 2016: Peptides
https://www.readbyqxmd.com/read/27796714/up-regulation-of-cathepsin-s-expression-by-hsp90-and-5-ht7-receptor-dependent-serotonin-signaling-correlates-with-triple-negativity-of-human-breast-cancer
#5
Jaya Gautam, Young Kyung Bae, Jung-Ae Kim
PURPOSE: Cathepsin S (CTSS) is expressed in a variety of cancers and stimulates tumor progression. However, the regulatory mechanism and role of CTSS in breast cancer progression are poorly understood. The aim of this study was to examine the relationships between CTSS expression and breast cancer grade and stage, and the signaling molecules involved in CTSS expression. METHODS: Immunohistochemical staining was performed in tissue microarray sections of 1451 human invasive breast cancer samples to determine epithelial (E-CTSS) and stromal CTSS (S-CTSS) expression...
October 27, 2016: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/27770782/triple-negative-breast-cancer-in-north-of-morocco-clinicopathologic-and-prognostic-features
#6
Touria Derkaoui, Joaira Bakkach, Mohamed Mansouri, Ali Loudiyi, Mohamed Fihri, Fatima Zahra Alaoui, Amina Barakat, Bouchra El Yemlahi, Hassan Bihri, Naima Ghailani Nourouti, Mohcine Bennani Mechita
BACKGROUND: Triple Negative Breast Cancer (TNBC) is defined by a lack of estrogen and progesterone receptor gene expression and by the absence of overexpression on HER2. It is associated to a poor prognosis. We propose to analyze the clinicopathologic and prognostic characteristics of this breast cancer subtype in a Mediterranean population originated or resident in the North of Morocco. METHODS: We conducted a retrospective study of 279 patients diagnosed with breast cancer between January 2010 and January 2015...
October 22, 2016: BMC Women's Health
https://www.readbyqxmd.com/read/27765921/triple-negative-breast-cancer-is-there-a-treatment-on-the-horizon
#7
Hui Yao, Guangchun He, Shichao Yan, Chao Chen, Liujiang Song, Thomas J Rosol, Xiyun Deng
Triple-negative breast cancer (TNBC), which accounts for 15-20% of all breast cancers, does not express estrogen receptor (ER) or progesterone receptor (PR) and lacks human epidermal growth factor receptor 2 (HER2) overexpression or amplification. These tumors have a more aggressive phenotype and a poorer prognosis due to the high propensity for metastatic progression and absence of specific targeted treatments. Patients with TNBC do not benefit from hormonal or trastuzumab-based targeted therapies because of the loss of target receptors...
September 27, 2016: Oncotarget
https://www.readbyqxmd.com/read/27721875/histomorphological-factors-predicting-the-response-to-neoadjuvant-chemotherapy-in-triple-negative-breast-cancer
#8
Yoon Yang Jung, Chang Lim Hyun, Min-Sun Jin, In Ae Park, Yul Ri Chung, Bobae Shim, Kyu Ho Lee, Han Suk Ryu
PURPOSE: There is no standard targeted therapy for the treatment of triple-negative breast cancer (TNBC). Therefore, its management heavily depends on adjuvant chemotherapy. Using core needle biopsy, this study evaluated the histological factors of TNBC predicting the response to chemotherapy. METHODS: One hundred forty-three TNBC patients who received single-regimen neoadjuvant chemotherapy (NAC) with the combination of doxorubicin, cyclophosphamide, and docetaxel were enrolled...
September 2016: Journal of Breast Cancer
https://www.readbyqxmd.com/read/27665540/nab-paclitaxel-for-the-treatment-of-triple-negative-breast-cancer-rationale-clinical-data-and-future-perspectives
#9
Francesco Schettini, Mario Giuliano, Sabino De Placido, Grazia Arpino
Triple-negative breast cancer (TNBC) accounts for ∼10-20% of breast cancers and is associated with relatively poor prognosis, earlier disease recurrence and higher number of visceral metastases. Despite an increasing understanding of the molecular heterogeneity of TNBC, clinical trials of targeted agents have thus far been disappointing; chemotherapy, in particular with anthracycline and taxanes, remains the backbone medical management for both early and metastatic TNBC. Nab-paclitaxel is a solvent-free, albumin-bound, nanoparticle formulation of paclitaxel and represents a novel formulation of an established, effective chemotherapeutic agent...
September 12, 2016: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/27494850/the-3-utr-signature-defines-a-highly-metastatic-subgroup-of-triple-negative-breast-cancer
#10
Lei Wang, Xin Hu, Peng Wang, Zhi-Ming Shao
Triple-negative breast cancer (TNBC) is a highly heterogeneous disease with an aggressive clinical course. Prognostic models are needed to chart potential patient outcomes. To address this, we used alternative 3'UTR patterns to improve postoperative risk stratification. We collected 327 publicly available microarrays and generated the 3'UTR landscape based on expression ratios of alternative 3'UTR. After initial feature filtering, we built a 17-3'UTR-based classifier using an elastic net model. Time-dependent ROC comparisons and Kaplan-Meier analyses confirmed an outstanding discriminating power of our prognostic model for TNBC patients...
August 1, 2016: Oncotarget
https://www.readbyqxmd.com/read/27462789/il-17e-synergizes-with-egf-and-confers-in-vitro-resistance-to-egfr-targeted-therapies-in-tnbc-cells
#11
Yacine Merrouche, Joseph Fabre, Herve Cure, Christian Garbar, Camille Fuselier, Jeremy Bastid, Frank Antonicelli, Reem Al-Daccak, Armand Bensussan, Jerome Giustiniani
Estrogen receptor-, progesterone receptor- and HER2-negative breast cancers, also known as triple-negative breast cancers (TNBCs), have poor prognoses and are refractory to current therapeutic agents, including epidermal growth factor receptor (EGFR) inhibitors. Resistance to anti-EGFR therapeutic agents is often associated with sustained kinase phosphorylation, which promotes EGFR activation and translocation to the nucleus and prevents these agents from acting on their targets. The mechanisms underlying this resistance have not been fully elucidated...
July 23, 2016: Oncotarget
https://www.readbyqxmd.com/read/27461138/novel-targets-for-paclitaxel-nano-formulations-hopes-and-hypes-in-triple-negative-breast-cancer
#12
REVIEW
Anita K Bakrania, Bhavesh C Variya, Snehal S Patel
Triple negative breast cancer is defined as one of the utmost prevailing breast cancers worldwide, possessing an inadequate prognosis and treatment option limited to chemotherapy and radiotherapy, creating a challenge for researchers as far as developing a specific targeted therapy is concerned. The past research era has shown several promising outcomes for TNBC such as nano-formulations of the chemotherapeutic agents already used for the management of the malignant tumor. Taking a glance at paclitaxel nano formulations, it has been proven beneficial in several researches in the past decade; nevertheless its solubility is often a challenge to scientists in achieving success...
September 2016: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
https://www.readbyqxmd.com/read/27456662/triple-negative-breast-cancer-a-tale-of-two-decades
#13
Arwa Mohammed Ali, Jawaher Ali Ansari, Nashwa Mohammed AbdelAziz, Waleed Aabozeed, Ahmed Warith, Khalid Alsaleh, Jean-Marc Nabholtz
Triple negative breast cancer (TNBC) is a heterogeneous disease entity constituting about 15% of breast cancer cases worldwide. TNBC is associated with poor prognosis and lack of sustained response to conventional chemotherapeutic agents. Tumoral heterogeneity and the presence of several subtypes of TNBC such as Basal like (BL)-1, BL-2, immune-modulatory, luminal androgen receptor, mesenchymal, and mesenchymal/stem like subtype and claudin low subtype, may explain some of the difficulties faced in managing this challenging disease subgroup...
July 25, 2016: Anti-cancer Agents in Medicinal Chemistry
https://www.readbyqxmd.com/read/27401886/biology-and-management-of-patients-with-triple-negative-breast-cancer
#14
REVIEW
Priyanka Sharma
UNLABELLED: : Triple-negative breast cancer (TNBC) accounts for 15% of all breast cancers and is associated with poor long-term outcomes compared with other breast cancer subtypes. Because of the lack of approved targeted therapy, at present chemotherapy remains the mainstay of treatment for early and advanced disease. TNBC is enriched for germline BRCA mutation, providing a foundation for the use of this as a biomarker to identify patients suitable for treatment with DNA-damaging agents...
September 2016: Oncologist
https://www.readbyqxmd.com/read/27386391/a-randomized-phase-i-trial-of-nanoparticle-albumin-bound-paclitaxel-with-or-without-mifepristone-for-advanced-breast-cancer
#15
Rita Nanda, Erica M Stringer-Reasor, Poornima Saha, Masha Kocherginsky, Jean Gibson, Bernadette Libao, Philip C Hoffman, Elias Obeid, Douglas E Merkel, Galina Khramtsova, Maxwell Skor, Thomas Krausz, Ronald N Cohen, Mark J Ratain, Gini F Fleming, Suzanne D Conzen
PURPOSE: Glucocorticoid receptor (GR) overexpression is associated with poor prognosis ER-negative breast cancer. GR antagonism with mifepristone increases chemotherapy-induced breast cancer cell death, therefore we conducted a phase I clinical trial of mifepristone and nab-paclitaxel in advanced breast cancer. METHODS: A novel randomized phase I design was used to assess the effect of mifepristone on nab-paclitaxel pharmacokinetics and toxicity. Patients were randomized to placebo or mifepristone for the first cycle; mifepristone was given to all for subsequent cycles...
2016: SpringerPlus
https://www.readbyqxmd.com/read/27363012/niclosamide-sensitizes-triple-negative-breast-cancer-cells-to-ionizing-radiation-in-association-with-the-inhibition-of-wnt-%C3%AE-catenin-signaling
#16
Lina Yin, Yun Gao, Xuxia Zhang, Jing Wang, Defang Ding, Yaping Zhang, Junxiang Zhang, Honghong Chen
Triple-negative breast cancer (TNBC) is one of the most difficult breast cancers to treat because there is no targeted treatment, and conventional cytotoxic chemotherapy followed by adjuvant radiation therapy is the standard of care for patients with TNBC. We herein reported that ionizing radiation (IR) induced Wnt3a, LRP6 and β-catenin expression and consequently activated Wnt/β-catenin signaling in TNBC MDA-MB-231, MDA-MB-468 and Hs578T cells. Moreover, depletion of β-catenin by shRNA sensitized TNBC cells to IR, whereas treatment of Wnt3a protein or overexpression of β-catenin resulted in radioresistance of TNBC cells...
July 5, 2016: Oncotarget
https://www.readbyqxmd.com/read/27293397/a-combination-of-targeted-therapy-with-chemotherapy-backbone-induces-response-in-a-treatment-resistant-triple-negative-mcl1-amplified-metastatic-breast-cancer-patient
#17
Siraj M Ali, Jessica Watson, Kai Wang, Jon H Chung, Caitlin McMahon, Jeffrey S Ross, Karel A Dicke
After failure of anthracycline- and platinum-based therapy, no effective therapies exist for management of metastatic triple-negative breast cancer (TNBC). We report a case of metastatic TNBC harboring MCL1 amplification, as identified by comprehensive genomic profiling in the course of clinical care. MCL1 is an antiapoptotic gene in the BCL2 family, and MCL1 amplification is common in TNBC (at least 20%). A personalized dose-reduced regimen centered on a combination of sorafenib and vorinostat was implemented, based on preclinical evidence demonstrating treatment synergy in the setting of MCL1 amplification...
January 2016: Case Reports in Oncology
https://www.readbyqxmd.com/read/27261365/outcome-of-pn0-triple-negative-breast-cancer-with-or-without-lymph-node-irradiation-a-single-institution-experience
#18
Jonathan Khalifa, Raphaelle Duprez-Paumier, Thomas Filleron, Magali Lacroix Triki, Eva Jouve, Florence Dalenc, Carole Massabeau
The optimal management of patients with pathologically node-negative triple-negative breast cancer (pN0 TNBC) remains unclear. We hypothesized that lymph node irradiation (LNI; internal mammary chain/periclavicular irradiation) had an impact on outcomes of pN0 TNBC. A cohort of 126 consecutive patients with pN0 TNBC treated between 2007 and 2010 at a single institute were included. All radiotherapy (breast/chest wall, ±LNI) was delivered adjuvantly, following completion of surgery ± chemotherapy. Tumors were reviewed and histologic features were described...
September 2016: Breast Journal
https://www.readbyqxmd.com/read/27221827/recent-progress-in-triple-negative-breast-cancer-research
#19
REVIEW
Fatima Zahra Mouh, Mohammed El Mzibri, Meriem Slaoui, Mariam Amrani
Triple-negative breast cancer (TNBC) is defined as a type of breast carcinoma that is negative for expression of oestrogene and progesterone hormone receptors (ER, PR) and HER2. This form of breast cancer is marked by its aggressiveness, low survival rate and lack of specific therapies. Recently, important molecular characteristics of TNBC have been highlighted and led to the identification of some biomarkers that could be used in diagnosis, as therapeutic targets or to assess the prognosis. In this review, we summarize recent progress in TNBC research focusing on the genetic and epigenetic alterations of TNBC and the potential use of these biomarkers in the targeted therapy for better management of TNBC...
2016: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/27061094/microglandular-adenosis-a-prime-suspect-in-triple-negative-breast-cancer-development
#20
Julia Ys Tsang, Gary Mk Tse
Microglandular adenosis (MGA) and atypical MGA (AMGA) are unusual lesions of the breast. They were once regarded as benign proliferative lesions and innocent bystanders. Several lines of evidence suggested that they could be neoplastic, clonal lesions and a non-obligate precursor for triple-negative breast cancers (TNBC). Recent work published in The Journal of Pathology by Guerini-Rocco and colleagues provided further evidence regarding the precursor-product relationship between MGA/AMGA and TNBC. Using a massively parallel sequencing approach, they demonstrated that MGA/AMGA, particularly those associated with TNBC, could be clonal neoplastic lesions showing clonal non-synonymous mutations, but none in pure MGA...
June 2016: Journal of Pathology
keyword
keyword
55830
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"